So if you think about the opportunity for us with the backdrop of what I just said, selling
the 360 portfolio, including X360 and Simplify in the Globus Medical accounts, selling Excelsius and Expendables in the NuVasive accounts, the ability to sell NSO and PRECICE in GMED and Globus existing orthopedic and trauma portfolio, all of
that should bring, hopefully, the context and some backdrop that we are confident in our ability to successfully integrate our commercial teams and as you ask, very confident in the complementary nature of the portfolio and how that creates value to
our patients, to our surgeons and to our shareholders.
[Portions of transcript unrelated to transaction omitted]
Operator
Our next question comes from
David Saxon with Needham & Company.
Joseph Scott Conway
Needham & Company, LLC, Research Division
This is Joseph calling for David. Maybe just wanted to do 2 questions around the overlap with Globus. I guess, just looking at the accounts
where you dont have any overlap with Globus, could you maybe talk about your main competitors in those accounts, if they are Globus?
J.
Christopher Barry
CEO & Director
I mean theres 8 to 10 companies that make up 80% of the market. So if its not us or Globus, its one of them. And depending on
where you are, it could be any one of those. So Medtronic is a market leader. So if you want to throw a dart at it, youd probably hit them first, but theres many others out there.
Joseph Scott Conway
Needham & Company, LLC,
Research Division
Okay. Yes, that makes sense. And then, I guess, internationally, if you could touch on that, what the overlap looks
like. Is it similar to the U.S.?
J. Christopher Barry
CEO & Director
Weve got
work to do there. But generally speaking, I cant speak for Globus here. But off the top of my head, I want to say they had low double-digit type of revenue representation of U.S. versus OUS, maybe 10% to 11%. But weve amassed
roughly about 25% of our revenue comes from markets outside the U.S., and thats growing substantially for us, 7.7% in constant currency in 2022.
So well get to the bottom of where we have overlapped. But safe to say, I think both of us in early innings and in low single-digit
share positions in most markets. Japan is a market that we have a significant amount of strength, as an example. Were the #2 share player, and theyre probably very lower a lower share player in that market. So thats clearly
a synergy opportunity.
Well be working through that as we go through the pre-integration
planning. We got a lot of work to do there. But at first glance, were optimistic that there is a significant opportunity and minimal overlap.
Now we havent gone to the granularity weve gone to in the U.S. yet, but we will. And like I said, were confident weve
got an opportunity there as well.
[Portions of transcript unrelated to transaction omitted]
Andrew Christopher Ranieri
Morgan Stanley, Research
Division
Just to start, really going back to the deal announcement, both the companies have kind of talked about free cash flow
generation being a key value driver of the deal. And Matt, I think I heard in your remarks that you talked about 2022 as a key investment year for sets. As youre thinking about 23, can you maybe talk about any specific areas where
youre continuing to push your foot down on the gas from an investment perspective in sets or anything that youre pulling back on? Just how should we kind of think about set deployment, set investment contributing to that 6% to 8% top
line growth for 23?